GlobalData Plc

NASH market as it stands now

Affecting more than 60 million people worldwide, and with no approved therapies, nonalcoholic steatohepatitis (NASH) presents a wealth of opportunities for drug developers. During the past few years, increased awareness has led to significant clinical activity in the disease area, with a plethora of companies vying for the first-to-market status for their products. Currently, there are eleven novel drugs in late-stage development for NASH across the seven major markets (US, France, Germany, Italy, UK, Spain and Japan), with anticipated launch dates in 2021-2025.

GlobalData Insights & Analysis related to this topic

Research was conducted to examine current trends and to understand the future potential of the pipeline agents in the NASH market. Based on insights gathered from key opinion leaders (KOLs), it is anticipated that the market will grow rapidly by more than forty-fold, from $618m in 2016 to around $25.3bn at the end of 2026. The initial uptake of the drugs will be slow, due to their high cost and reimbursement issues. Towards the end of the forecast period, it is expected that these drugs will displace the currently available off-label treatments, the driver for growth being the launch of diagnostic biomarkers which will provide evidence of treatment outcomes and enhance reimbursement prospects.

Analyst’s Opinion

GlobalData’s Managing Analyst within Immunology, Lakshmi Dharmarajan explains that this analysis has “highlighted the significant opportunity in the NASH market for the development of drugs with different mechanisms-of-action in order to effectively treat the heterogeneous patient population.” In addition, the analysis includes insights from KOLs about which of the pipeline drugs (in Phase IIb and Phase III) appear to be most promising. The research further underlines the types of R&D strategies that should be employed by pharmaceutical companies in order to succeed in the competitive NASH market, all of which will be explored in the ‘Understanding the NASH Market Landscape’ webinar.

– Comments provided by Lakshmi Dharmarajan, Managing Analyst at GlobalData.

– Information based on GlobalData’s webinar: Understanding the NASH Market Landscape

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends…